- |||||||||| Enrollment closed, Trial primary completion date: Regulation of Cervical Mucus Secretion (clinicaltrials.gov) - Oct 27, 2017
P4, N=10, Active, not recruiting, Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Oct 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Aug 2017
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
Trial suspension, Trial primary completion date, PD(L)-1 Biomarker: Pembrolizumab +/- SD-101 in Hormone-Na (clinicaltrials.gov) - Oct 16, 2017 P2, N=42, Suspended, N=30 --> 36 Recruiting --> Suspended | Trial primary completion date: Apr 2019 --> Apr 2020
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Enrollment closed: Females, Aging, Metabolism, and Exercise (clinicaltrials.gov) - Jul 18, 2017 P=N/A, N=132, Active, not recruiting, Trial primary completion date: Oct 2017 --> Oct 2018 Recruiting --> Active, not recruiting
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Preservation of Ovarian Function After Hematopoietic Cell Transplant (clinicaltrials.gov) - Jul 17, 2017 P2, N=19, Terminated, Recruiting --> Active, not recruiting N=47 --> 19 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2014 --> Apr 2015
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Biomarker, Enrollment open: Menopausal Sleep Fragmentation and Body Fat Gain (clinicaltrials.gov) - Jul 16, 2017 P4, N=58, Recruiting, N=47 --> 19 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2014 --> Apr 2015 Not yet recruiting --> Recruiting
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
Enrollment open, PD(L)-1 Biomarker: Pembrolizumab +/- SD-101 in Hormone-Na (clinicaltrials.gov) - Jun 8, 2017 P2, N=42, Recruiting, Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion: A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids (clinicaltrials.gov) - Jun 5, 2017 P3, N=288, Completed, Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
Enrollment closed, Enrollment change, Metastases: Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer (clinicaltrials.gov) - May 18, 2017 P1, N=26, Active, not recruiting, N=900 --> 239 Recruiting --> Active, not recruiting | N=50 --> 26
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
Enrollment change, PD(L)-1 Biomarker: Pembrolizumab +/- SD-101 in Hormone-Na (clinicaltrials.gov) - Apr 25, 2017 P2, N=42, Not yet recruiting, Recruiting --> Active, not recruiting N=60 --> 42
- |||||||||| Yervoy (ipilimumab) / BMS
Trial completion, Enrollment change, Trial primary completion date: Ipilimumab + Androgen Depravation Therapy in Prostate Cancer (clinicaltrials.gov) - Apr 12, 2017 P2, N=30, Completed, Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2018 --> Dec 2018 Active, not recruiting --> Completed | N=48 --> 30 | Trial primary completion date: Jun 2018 --> Apr 2017
|